Trudy Brown

Recommended Articles

• The Metabolic and Cardiovascular Costs of Untreated Sleep Apnea

  Among many other diseases and conditions that commonly remain unnoticed and are not usually diagnosed at first, sleep apnea has arisen as one of the most dangerous diseases affecting a large percentage of American population. However, whether the person is aware or not about this condition, the...

• Multiple Sclerosis Treatments Are Becoming More Effective, but Are Underfunded

  Multiple sclerosis is considered a relatively rare disease, but a recent MS guideline published by the National Institute for Health and Care Excellence stated that with more than 400,000 cases in the US alone, MS has become the leading cause of physical disability in working age adults.Although...

• Are There Medications to Treat Shin Splints?

  Shin splints refer the pain your feel along the inner aspect of your shin bone. It usually follows high intensity physical activities and in sports like basketball, soccer and tennis. Shin splints are a common problem among runners and other athletes.The best way to treat a shin splint is by giving...

• Agony of a Little Girl Diagnosed with Sleep Apnea

  People often say they slept like a baby after a restful night of sleep. However, that is not always the case, especially for kids suffering from obstructive sleep apnea. Sadly, most parents are not aware of this issue and it can become a very difficult problem to deal with, a problem that can affect...

• Celiac Disease: Get Diagnosed

  Most often people have extra intestinal symptoms, such as migraine, peripheral neuropathy, joint pains, seizures, short stature, pubertal delay, and infertility. These presentations are not commonly tested for celiac disease, therefore, majority remains undiagnosed. ...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...